Earnings Are Growing at Baolingbao BiologyLtd (SZSE:002286) but Shareholders Still Don't Like Its Prospects
Earnings Are Growing at Baolingbao BiologyLtd (SZSE:002286) but Shareholders Still Don't Like Its Prospects
For many investors, the main point of stock picking is to generate higher returns than the overall market. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Baolingbao Biology Co.,Ltd. (SZSE:002286) shareholders, since the share price is down 46% in the last three years, falling well short of the market decline of around 11%. Shareholders have had an even rougher run lately, with the share price down 14% in the last 90 days. But this could be related to the weak market, which is down 8.8% in the same period.
对于许多投资者来说，选股的主要着眼点是产生高于整体市场的回报。但几乎可以肯定的是，有时你会买入低于市场平均回报率的股票。不幸的是，从长远来看，情况就是这样宝灵宝生物股份有限公司。(SZSE：002286)股东，因为股价在过去三年中下跌了46%，远远低于市场约11%的跌幅。股东们最近的表现更加艰难，股价在过去90天里下跌了14%。但这可能与市场疲软有关，同期市场下跌8.8%。
If the past week is anything to go by, investor sentiment for Baolingbao BiologyLtd isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果以过去一周为标准，投资者对宝灵宝生物股份有限公司的情绪并不乐观，所以让我们看看基本面和股价之间是否存在错配。
View our latest analysis for Baolingbao BiologyLtd
查看我们对宝灵宝生物有限公司的最新分析
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
本杰明·格雷厄姆(Benjamin Graham)的原话是：短期内，市场是一台投票机，但从长远来看，它是一台称重机。一种不完美但简单的方法来考虑市场对一家公司的看法是如何改变的，那就是将每股收益(EPS)的变化与股价走势进行比较。
During the unfortunate three years of share price decline, Baolingbao BiologyLtd actually saw its earnings per share (EPS) improve by 10% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.
在不幸的股价下跌的三年里，宝灵宝生物有限公司实际上看到其每股收益(EPS)以每年10%的速度增长。考虑到股价的反应，人们可能会怀疑，每股收益不是这段时间内业务表现的良好指南(可能是因为一次性的亏损或收益)。或者，该公司过去被过度炒作，因此其增长令人失望。
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
由于每股收益的变化似乎与股价的变化没有相关性，因此值得看看其他指标。
The modest 1.1% dividend yield is unlikely to be guiding the market view of the stock. Revenue is actually up 11% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating Baolingbao BiologyLtd further; while we may be missing something on this analysis, there might also be an opportunity.
1.1%的适度股息收益率不太可能指导市场对该股的看法。营收实际上在过去三年里增长了11%，因此股价下跌似乎也与营收无关。可能值得进一步调查宝灵宝生物有限公司；虽然我们可能在这一分析上遗漏了一些东西，但也可能存在机会。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下图显示了收益和收入随时间的变化情况(如果您点击该图，您可以看到更多详细信息)。
This free interactive report on Baolingbao BiologyLtd's balance sheet strength is a great place to start, if you want to investigate the stock further.
这免费如果你想进一步调查宝灵宝生物股份有限公司的股票，那么关于该公司资产负债表实力的互动报告是一个很好的起点。
A Different Perspective
不同的视角
While the broader market lost about 6.5% in the twelve months, Baolingbao BiologyLtd shareholders did even worse, losing 15% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 7%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Baolingbao BiologyLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Baolingbao BiologyLtd , and understanding them should be part of your investment process.
虽然大盘在过去12个月里下跌了约6.5%，但宝灵宝生物股份有限公司的股东表现更差，下跌了15%(甚至包括股息)。话虽如此，在下跌的市场中，一些股票不可避免地会被超卖。关键是要密切关注基本面的发展。较长期的投资者不会如此沮丧，因为他们在五年内每年会获得7%的收益。最近的抛售可能是一个机会，因此可能值得查看基本面数据，以寻找长期增长趋势的迹象。跟踪股价的长期表现总是很有趣的。但要更好地理解宝灵宝生物有限公司，我们需要考虑许多其他因素。例如，考虑一下无处不在的投资风险幽灵。我们已经确定了三个警告信号与宝灵宝生物有限公司合作，了解他们应该是你投资过程的一部分。
Of course Baolingbao BiologyLtd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然了宝灵宝生物股份有限公司可能不是最好的股票。所以你可能想看看这个免费成长型股票的集合。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意，本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗？担心内容吗？ 保持联系直接与我们联系。或者，也可以给编辑组发电子邮件，地址是implywallst.com。
本文由Simply Wall St.撰写，具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论，我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议，也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意，我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。